Medistim Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 04/12 07:41

Medistim (OB:MEDI) Full Year 2024 Results

Key Financial Results

  • Revenue: kr562.6m (up 8.0% from FY 2023).
  • Net income: kr103.8m (flat on FY 2023).
  • Profit margin: 19% (down from 20% in FY 2023). The decrease in margin was driven by higher expenses.
  • EPS: kr5.67.
revenue-and-expenses-breakdown
OB:MEDI Revenue and Expenses Breakdown April 12th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medistim Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 4.7%.

The primary driver behind last 12 months revenue was the Sale of Own Products segment contributing a total revenue of kr472.8m (84% of total revenue). The largest operating expense was General & Administrative costs, amounting to kr185.1m (54% of total expenses). Explore how MEDI's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Europe.

Performance of the market in Norway.

The company's shares are down 2.4% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Medistim's balance sheet and an in-depth analysis of the company's financial position.